Counterfeit medicines online: how digital pharmacy networks are becoming a complex investigative challenge

Counterfeit medicines online

How digital pharmacy networks are becoming a complex investigative challenge

Counterfeit medicines sold online are creating an increasingly complex challenge for consumer protection and public health investigators.

What was once primarily a physical supply chain issue has evolved into a connected digital ecosystem. Rogue online pharmacies can now operate alongside organised criminal networks, international shipping routes and offshore intermediaries.

Rather than dealing with isolated counterfeit products, investigators may uncover entire distribution networks. These networks can advertise medicines through search engines and social media, distribute products internationally and route payments through complex financial infrastructure.

For healthcare regulators and Trading Standards teams, understanding the networks behind counterfeit medicines online is therefore becoming increasingly important.

Successful investigations rarely rely on a single dataset. Instead, investigators can combine commercial records, regulatory data, open-source intelligence and digital evidence to build a clearer picture of the wider network.

This connected approach reflects the wider value of turning disjointed data into actionable fraud intelligence.

Understanding the scale of counterfeit medicines

The global scale of counterfeit medicines is significant.

The World Health Organization estimates that around one in ten medical products in low and middle-income countries are substandard or falsified. Counterfeit medicines form part of a global illicit trade worth billions.

Criminals deliberately design counterfeit medicines to imitate legitimate pharmaceutical products. However, these products may contain incorrect active ingredients, unsafe dosages or other potentially harmful substances.

Investigations have also uncovered counterfeit products containing dangerous materials. Even when a product contains the correct active ingredient, an incorrect dosage can make it ineffective or unsafe.

Despite strong regulatory frameworks in many countries, counterfeit medicines continue to enter informal online marketplaces and legitimate supply chains.

The rise of illegal online pharmacies

Online pharmacies have become an important distribution channel for counterfeit medicines.

Many illegal websites imitate legitimate retailers and offer prescription medicines without requiring a valid prescription. Products advertised can include:

• Antibiotics
• Painkillers
• Antidepressants
• Weight-loss medications
• Anabolic steroids
• Hair-loss treatments
• Diagnostic testing kits

Estimates suggest that one in ten people in the UK may have purchased fake medical products online.*

However, these websites rarely operate alone.

A single criminal network may operate dozens or even hundreds of domains simultaneously. Criminals can also rotate these domains frequently to reduce the impact of enforcement action.

When authorities seize or close one website, another can quickly appear under a different domain. Crucially, the replacement may use the same infrastructure, payment routes or other digital assets.

This behaviour is similar to the churn-and-burn websites reshaping financial crime, where criminals repeatedly replace short-lived online infrastructure.

As a result, investigators need to move beyond analysing individual websites and start examining the networks connecting them.

Enforcement and global cooperation

The international response to counterfeit medicines reflects the scale of the threat.

Large operations such as Operation Pangea bring law enforcement agencies and health regulators together to disrupt illegal pharmaceutical supply chains.

Recent operations have resulted in:**

• Millions of counterfeit medicines seized worldwide
• More than three million medicines and devices seized in the UK
• More than 113,000 illegal pharmacy websites removed or blocked
• Arrests and coordinated search warrants across multiple jurisdictions

These operations demonstrate both the scale of the trade and the resilience of the criminal networks behind it.

Closing individual websites can temporarily disrupt distribution. However, the infrastructure supporting those websites may remain intact.

Therefore, investigators need to identify the networks, individuals and infrastructure that enable illegal pharmaceutical distribution. Doing so can create opportunities for longer-term disruption.

OSINT: from website detection to network mapping

Open-source intelligence can play an important role in investigations into counterfeit medicines.

Initial detection may begin with information available through open sources. For example, investigators may identify suspicious websites through indicators such as:

• Prescription medicines offered without a prescription
• Poor grammar or unusual website design
• Aggressive advertising or pop-up marketing
• Suspiciously low prices
• Fabricated or duplicated customer reviews
• Domain names based around specific medicines
• Company information that investigators cannot verify

Individually, these indicators do not necessarily confirm illegal activity. However, analysing several indicators together can reveal patterns associated with wider distribution networks.

Domain infrastructure, company records, payment routes and online advertising footprints may also expose links between websites that initially appear unrelated.

Once investigators identify and map these relationships, they can begin examining the individuals or organisations controlling the wider network.

This is where OSINT in financial crime investigations can provide useful investigative context. The same principles of connecting identities, infrastructure and online activity can help teams understand complex criminal networks.

The challenge of manual analysis

Investigations into counterfeit medicine networks can involve significant volumes of digital information.

A single operation may connect multiple domains, hosting providers, payment channels and corporate entities. Furthermore, activity can span several years as websites appear and disappear in response to enforcement.

Manually analysing these relationships can consume significant investigative resources.

Individuals and organisations may appear under different names across multiple jurisdictions. At the same time, criminals can obscure infrastructure links across separate data sources.

Investigative technology can help regulatory teams bring these signals together more efficiently.

Altia is working with several Trading Standards departments on a pilot project exploring how investigative platforms can help identify suspicious online pharmaceutical activity.

The aim is not to replace investigator expertise. Instead, technology can help teams connect open-source signals, commercial data and regulatory information when developing early investigative hypotheses.

OSINT Investigator helps investigation teams search open sources and connect information as part of a wider investigative workflow.

Organised crime and consumer harm

Counterfeit pharmaceuticals are not only a public health issue. They can also form part of wider organised criminal activity.

Proceeds from illegal pharmaceutical sales may support fraud, money laundering and other forms of illicit trade.

Consequently, disrupting the networks behind counterfeit medicines can have an impact beyond the pharmaceutical market itself.

For investigators and regulators, preventing dangerous medicines from reaching consumers remains an important priority. However, identifying the networks responsible can also help disrupt the revenue streams supporting wider criminal activity.

This wider network-based approach is increasingly important as fraud becomes more digitally connected.

A practical investigative approach

Successful investigations into counterfeit medicine networks require an integrated analytical approach.

Rather than focusing solely on individual domains, investigators should examine the wider ecosystem surrounding digital pharmaceutical distribution.

Common investigative indicators can include:

• Groups of pharmacy websites sharing infrastructure
• Repeated use of intermediaries with limited or obscured operational footprints
• Payment routes through apparently unrelated jurisdictions
• Shipping patterns inconsistent with legitimate pharmaceutical supply chains
• Hidden ownership across multiple corporate entities

These signals rarely appear in isolation. Therefore, the challenge lies in identifying where they intersect.

Connecting digital information with wider intelligence can help investigators uncover relationships between domains, organisations and individuals.

The principles are similar to those explored in OSINT and financial intelligence in economic crime. Individual pieces of information become much more valuable when investigators can understand the relationships between them.

Conclusion: investigating networks, not websites

The challenge surrounding counterfeit medicines online is not necessarily a lack of information.

In many cases, investigators have access to large volumes of data across open sources, regulatory systems and commercial records. The difficulty lies in connecting those individual data points into a coherent investigative picture.

For Trading Standards teams and regulatory investigators, network-focused investigations can therefore provide greater value than examining individual websites in isolation.

Illegal pharmacy websites are often only the visible part of a wider criminal operation. Identifying the infrastructure, organisations and individuals supporting them can create opportunities to disrupt the underlying supply chain.

As online commerce continues to reshape pharmaceutical distribution, investigative methods will need to evolve alongside it.

Open-source intelligence, regulatory expertise and digital analysis will remain important tools for identifying and disrupting counterfeit pharmaceutical networks.

Q&A

What are counterfeit medicines?

Counterfeit medicines are unauthorised pharmaceutical products designed to imitate legitimate medicines. They may contain incorrect ingredients, unsafe dosages or harmful substances.

Criminals commonly distribute these products through illegal online pharmacies and other unauthorised channels.

Why are fake medicines commonly sold online?

Online platforms allow criminal networks to market and distribute medicines across jurisdictions with relatively little physical infrastructure.

Furthermore, criminals can create and replace websites quickly when authorities take enforcement action. This makes it harder to disrupt a network by targeting individual websites alone.

How do investigators identify illegal pharmacy websites?

Investigators can use open-source information to identify suspicious indicators.

These may include prescription medicines offered without appropriate prescriptions, unusual domain registration patterns and suspicious website design. Links between multiple websites using shared infrastructure can also provide valuable intelligence.

Why are counterfeit medicine networks difficult to investigate?

Evidence can sit across website infrastructure, corporate records, shipping information and payment systems.

When investigators analyse these datasets separately, relationships within the wider network can remain hidden. Therefore, connecting information across multiple sources is often essential.

How can investigations disrupt counterfeit medicine networks?

Investigators can focus on identifying the infrastructure, organisations and individuals responsible for networks of illegal pharmaceutical websites.

Removing individual websites can provide temporary disruption. However, targeting the infrastructure and people supporting those websites can help investigators address the wider network rather than its individual endpoints.

Sources

* Miaa

** gov.uk